D-Glutamate

D-Glutamate

SCHEMBL247753

NC(CC(=O)O)C(=O)O.NC(CCC(=O)O)C(=O)O

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A2SLC6A3

The experimentally established mechanism targets of D-Glutamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 2/20 0.82
GRM6 O15303 2/20 0.82
GRM7 Q14831 2/20 0.82
GRM4 Q14833 2/20 0.82
GRIN2D O15399 1/20 0.82
GRIN3B O60391 1/20 0.82
GSR P00390 1/20 0.82
CYP1A2 P05177 1/20 0.82
GRIK1 P39086 1/20 0.82
GRM5 P41594 1/20 0.82
GRIA1 P42261 1/20 0.82
GRIA2 P42262 1/20 0.82
GRIA3 P42263 1/20 0.82
SLC1A3 P43003 1/20 0.82
SLC1A2 P43004 1/20 0.82
SLC1A1 P43005 1/20 0.82
GRIA4 P48058 1/20 0.82
GRIN1 Q05586 1/20 0.82
GRIN2A Q12879 1/20 0.82
GRIK2 Q13002 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Glutamate SCHEMBL7430337 1.00 GRM8 (0.82) GRM8GRM6GRM7GRM4GRIN2D
D-Glutamate SCHEMBL17184330 1.00 GRM8 (0.82) GRM8GRM6GRM7GRM4GRIN2D
Glutamic Acid SCHEMBL8007972 1.00 GRM8 (0.82) GRM8GRM6GRM7GRM4GRIN2D
Glutamic Acid SCHEMBL6528977 1.00 GRM8 (0.82) GRM8GRM6GRM7GRM4GRIN2D
Glutamic Acid SCHEMBL17184331 1.00 GRM8 (0.82) GRM8GRM6GRM7GRM4GRIN2D
Glutamic Acid SCHEMBL135757 1.00 GRM8 (0.82) GRM8GRM6GRM7GRM4GRIN2D
Glutamic Acid SCHEMBL1661037 1.00 GRM8 (0.82) GRM8GRM6GRM7GRM4GRIN2D
D-Glutamate SCHEMBL418133 1.00 GRM8 (0.82) GRM8GRM6GRM7GRM4GRIN2D
Glutamic Acid SCHEMBL16584589 1.00 GRM8 (0.82) GRM8GRM6GRM7GRM4GRIN2D
D-Glutamate SCHEMBL9817837 1.00 GRM8 (0.82) GRM8GRM6GRM7GRM4GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1489 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022256643-A1 TISSUE-ENGINEERED ROSTRAL MIGRATORY STREAM FOR NEURONAL REPLACEMENT THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2022-12-08 WO claimed
US-11390890-B2 Dibasic organic acid producing strain and preparation and application of same TIANJIN INSTITUTE OF INDUSTRIAL BIOTECHNOLOGY, CHINESE ACADEMY OF SCIENCES (CN) 2022-07-19 US claimed
CN-113647359-A Construction method of tunicamycin injection induced acute liver injury mouse model 芜湖职业技术学院 2021-11-16 CN claimed
EP-3274709-B1 METHODS OF PROGNOSING MILD TRAUMATIC BRAIN INJURIES TRANSLATIONAL GENOMICS RES INST (US) 2021-07-07 EP claimed
WO-2021032271-A1 INDUCTION OF FUNCTIONAL ASTROCYTES FROM PLURIPOTENT STEM CELLS LU LICENSE AB (SE) 2021-02-25 WO claimed
US-20200347415-A1 DIBASIC ORGANIC ACID PRODUCING STRAIN AND PREPARATION AND APPLICATION OF SAME TIANJIN INST IND BIOTECHNOLOGY CAS (CN) 2020-11-05 US claimed
WO-2019191650-A1 COMPOSITIONS AND METHODS FOR TARGETING CELLS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2019-10-03 WO claimed
US-20190241899-A1 Methods of Crispr Mediated Genome Modulation in V. Natriegens UNITED STATES DEPARTMENT OF ENERGY 2019-08-08 US claimed
EP-3501511-A1 MEANS FOR PREVENTING AND TREATING BRAIN METASTASIS Fundación Centro Nacional De Investigaciones Oncológicas Carlos III (ES) 2019-06-26 EP claimed
US-20190160188-A1 Radiolabeled Alpha-Melanocyte Stimulating Hormone Hybrid Peptide for Melanoma Targeting STC UNM (US) 2019-05-30 US claimed
US-5739273-A CONJUGATED BACTERIORHODOPSIN FOR DRUG DELIVERY YALE UNIVERSITY (US) 1998-04-14 US claimed
EP-0759750-A1 COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SHAPIRO, Howard, K. (US) 1997-03-05 EP claimed
WO-1995031194-A1 COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SHAPIRO HOWARD K (US) 1995-11-23 WO claimed
EP-0564561-A4 PEPTIDES KETOAMIDES, KETOACIDS, AND KETOESTERS GEORGIA TECH RES INST (US) 1994-08-10 EP claimed
EP-0564561-A1 PEPTIDES KETOAMIDES, KETOACIDS, AND KETOESTERS GEORGIA TECH RESEARCH CORPORATION (US) 1993-10-13 EP claimed
EP-0548228-A1 LIPASE VARIANTS NOVO NORDISK A/S (DK) 1993-06-30 EP claimed
WO-1992012140-A1 PEPTIDES KETOAMIDES, KETOACIDS, AND KETOESTERS GEORGIA TECH RESEARCH CORPORATION (US) 1992-07-23 WO claimed
WO-1992005249-A1 LIPASE VARIANTS NOVO NORDISK A/S (DK) 1992-04-02 WO claimed
CN-1043134-A ANTICOAGULANT PEPTIDES MERRELL DOW PHARMA (US) 1990-06-20 CN claimed
US-4488989-A ESTERS, DETERGENTS, STORAGE STABILITY LEVER BROTHERS COMPANY (US) 1984-12-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190160188-A1 Radiolabeled Alpha-Melanocyte Stimulating Hormone Hybrid Peptide for Melanoma Targeting MC1R, MC3R, MC4R GRM8 4271/4885GRM6 3964/4885GRM7 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.